ALLM

Cat. No.:	HY-118355
CAS No.:	110115-07-6
Molecular Formula:	$C_{19}H_{35}N_3O_4S$
Molecular Weight:	401.56
Target:	Proteasome; Cathepsin
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	ALLM (Calpain inhibitor II) is a potent inhibitor of calpain and cathepsin proteases. ALLM inhibits neuronal cell death and improves chronic neurological function after spinal cord injury (SCI)[1][2].
In Vivo	ALLM (Calpain inhibitor II) (0.5 mg/kg) is injected every 24 h for 5 days after SCI and inhibits the activation of calpain but not that of caspase 3. ALLM prevents this neuronal cell death[2]. ALLM (0.05-2.5 mg/kg; i.p.; every 24 h for 1 week) reduces motor disturbances after spinal cord injury (SCI)[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult male Wistar rats (280-300g) (spinal cord injury model)[2]
Dosage:	0.05, 0.5, and 2.5 mg/kg
Administration:	Intraperitoneally; every 24 h for 1 week
Result:	Showed significantly better motor function.

REFERENCES

[1]. Stangl V, et al. Long-term up-regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin-proteasome pathway. FASEB J. 2004 Feb;18(2):272-9.

[2]. Arataki S, et al. Calpain inhibitors prevent neuronal cell death and ameliorate motor disturbances after compression-induced spinal cord injury in rats. J Neurotrauma. 2005 Mar;22(3):398-406.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA